Abstract | OBJECTIVE: METHODS: RESULTS: The incidence of ≥Grade 3 dermatitis did not differ between the two groups. However, as secondary endpoints of this study, the incidence of ≥Grade 2 dermatitis was lower in Group A than B (62.6 vs. 94.4%; P < 0.05), and the duration of ≥Grade 1 dermatitis was shorter in Group A than B (44.8 vs. 56.7%; P < 0.01), as was the duration of ≥Grade 2 dermatitis (16.5 vs. 26.5%; P < 0.05). CONCLUSIONS:
|
Authors | Takayuki Imai, Kazuto Matsuura, Yukinori Asada, Shun Sagai, Katsunori Katagiri, Eiichi Ishida, Daisuke Saito, Rei Sadayasu, Hitoshi Wada, Shigeru Saijo |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 44
Issue 5
Pg. 422-7
(May 2014)
ISSN: 1465-3621 [Electronic] England |
PMID | 24688085
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Dipeptides
- Valerates
- arginyl-glutamine
- beta-hydroxyisovaleric acid
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Chemoradiotherapy
(adverse effects)
- Dietary Supplements
- Dipeptides
(administration & dosage)
- Female
- Head and Neck Neoplasms
(drug therapy, pathology, radiotherapy, therapy)
- Humans
- Incidence
- Male
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- Radiodermatitis
(diagnosis, prevention & control)
- Radiotherapy Dosage
- Severity of Illness Index
- Treatment Outcome
- Valerates
(administration & dosage)
|